Plozasiran, an RNA Interference Agent Targeting APOC3, for …
May 28, 2024 · We carried out a 48-week, phase 2b, double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of plozasiran, a hepatocyte-targeted APOC3 small interfering RNA, in...
Plozasiran: What is it and is it FDA approved? - Drugs.com
Nov 18, 2024 · Plozasiran is a first-in-class investigational RNA interference (RNAi) therapeutic in development for the treatment of familial chylomicronemia syndrome.
Plozasiran for Managing Persistent Chylomicronemia and …
Sep 2, 2024 · Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides. In a phase 3 trial, we randomly assigned 75 patients with...
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The
Jul 1, 2024 · Objective: To determine the tolerability, efficacy, and dose of plozasiran, an APOC3-targeted small interfering-RNA (siRNA) drug, for lowering triglyceride and apolipoprotein C3 (APOC3, regulator of triglyceride metabolism) levels and evaluate its effects on other lipid parameters in patients with sHTG.
Plozasiran, an RNA Interference Agent Targeting APOC3, for …
Sep 12, 2024 · In this randomized, controlled trial involving participants with mixed hyperlipidemia, plozasiran, as compared with placebo, significantly reduced triglyceride levels at 24 weeks. A clinical outcomes trial is warranted.
Arrowhead Pharmaceuticals Presents New Data at AHA24 from …
Nov 16, 2024 · Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran.
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy …
Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism.
Arrowhead Pharmaceuticals Announces Acceptance of New Drug …
1 day ago · About Plozasiran. Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism.
Plozasiran Reduces Triglyceride Levels by 74% at 24 Weeks
Apr 7, 2024 · In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of 74% after 24 weeks of use without causing any significant safety concerns, according to research presented at the American College of Cardiology’s Annual Scientific ...
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
Objective To determine the tolerability, efficacy, and dose of plozasiran, an APOC3-targeted small interfering–RNA (siRNA) drug, for lowering triglyceride and apolipoprotein C3 (APOC3, regulator of triglyceride metabolism) levels and evaluate its effects on other lipid parameters in …